Literature DB >> 11858910

Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY Antimicrobial Surveillance Program.

Ronald N Jones1, Phyllis Della-Latta, Lillian V Lee, Douglas J Biedenbach.   

Abstract

A patient case report describes an Enterococcus faecium strain isolated from a blood culture that was resistant to linezolid (MIC, 8 microg/mL; G2576U mutation of 23S rRNA). Co-resistances were identified for vancomycin, ampicillin, macrolides, fluoroquinolones, chloramphenicol, rifampin, gentamicin (high-level), nitrofurantoin and trimethoprim/sulfamethoxazole. Etest (AB BIODISK, Solna, Sweden) and disk diffusion results also detected the oxazolidinone resistance pattern. Laboratories should be aware of the rare possibility of these strains occurring during linezolid therapy or spontaneously (this case) in contemporary practice, and have in vitro susceptibility methods available capable of detecting oxazolidinone resistance.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11858910     DOI: 10.1016/s0732-8893(01)00333-9

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  18 in total

1.  Detection of oxazolidinone-resistant Enterococcus faecalis and Enterococcus faecium strains by real-time PCR and PCR-restriction fragment length polymorphism analysis.

Authors:  Neil Woodford; Luke Tysall; Cressida Auckland; Mark W Stockdale; Andrew J Lawson; Rachel A Walker; David M Livermore
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

2.  Molecular detection of linezolid resistance in Enterococcus faecium and Enterococcus faecalis by use of 5' nuclease real-time PCR compared to a modified classical approach.

Authors:  Guido Werner; Birgit Strommenger; Ingo Klare; Wolfgang Witte
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

3.  Emergence of linezolid resistance in Enterococcus faecium not dependent on linezolid treatment.

Authors:  M G Bonora; M Ligozzi; A Luzzani; M Solbiati; E Stepan; R Fontana
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-03       Impact factor: 3.267

4.  In vitro activities of the Rx-01 oxazolidinones against hospital and community pathogens.

Authors:  Laura Lawrence; Paul Danese; Joe DeVito; Francois Franceschi; Joyce Sutcliffe
Journal:  Antimicrob Agents Chemother       Date:  2008-03-03       Impact factor: 5.191

5.  R chi-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance.

Authors:  Eugene Skripkin; Timothy S McConnell; Joseph DeVito; Laura Lawrence; Joseph A Ippolito; Erin M Duffy; Joyce Sutcliffe; François Franceschi
Journal:  Antimicrob Agents Chemother       Date:  2008-07-28       Impact factor: 5.191

Review 6.  Newer treatment options for skin and soft tissue infections.

Authors:  Murugan Raghavan; Peter K Linden
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  Linezolid-resistant Enterococcus faecalis isolated from a cord blood transplant recipient.

Authors:  Imad Dibo; Satish K Pillai; Howard S Gold; Maria R Baer; Meir Wetzler; James L Slack; Peggy A Hazamy; Donna Ball; Chiu Bin Hsiao; Philip L McCarthy; Brahm H Segal
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

8.  Mutations in the DNA mismatch repair proteins MutS and MutL of oxazolidinone-resistant or -susceptible Enterococcus faecium.

Authors:  Rob J Willems; Janetta Top; Derek J Smith; David I Roper; Sarah E North; Neil Woodford
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

9.  Emergence of increasing linezolid-resistance in enterococci in a post-outbreak situation with vancomycin-resistant Enterococcus faecium.

Authors:  B Schulte; A Heininger; I B Autenrieth; C Wolz
Journal:  Epidemiol Infect       Date:  2007-09-25       Impact factor: 2.451

10.  First characterization of a cluster of VanA-type glycopeptide-resistant Enterococcus faecium, Colombia.

Authors:  Diana Panesso; Sigifredo Ospina; Jaime Robledo; María Claudia Vela; Julieta Peña; Orville Hernández; Jinnethe Reyes; César A Arias
Journal:  Emerg Infect Dis       Date:  2002-09       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.